Clinical study of Xuebijing Injection combined with ribavirn in treatment of severe viral pneumonia
Objective To investigate the clinical effect of Xuebijing Injection combined with ribavirn in treatment of severe viral pneumonia. Methods A total of 86 patients diagnosed with severe viral pneumonia in the ICU of the First Affiliated Hospital of Anhui University of Science and Technology from January 2021 to December 2023 were included. A computer-generated random number table was used to randomly divide the patients into control group (38 cases) and treatment group (36 cases) according to the order of admission. Patients in the control group were iv administered with Ribavirn Injection,0.5 g was added to 0.9％ sodium chloride solution 250 mL,once daily. Patients in the treatment group were iv administered with Xuebijing Injection on the basis of the control group,50 mL/time,twice daily. Both groups were treated continuously for 2 weeks. The clinical efficacy,general clinical indexes,lung imaging improvement and laboratory related indexes of the two groups were observed. Results After treatment,the total effective rate of the treatment group and control group was 91.67％ and 81.58％,respectively,and there was no statistical significance between two groups. Compared with control group,the clinical recovery time,fever remission time and average hospital stay in treatment group were significantly shorter than those in the control group,but the lung imaging improvement rate and clinical recovery rate was significantly higher than those in control group (P<0.05). After treatment,the levels of lymphocyte,C-reactive protein (CRP),procalcitonin and creatine kinase MB (CK-MB) in two groups were significantly decreased compared with before treatment (P<0.05). After treatment,the levels of lymphocyte,CRP,procalcitonin and CK-MB in treatment group were lower than those in control group (P<0.05). Conclusion Xuebijing Injection combined with ribavirn has significant efficacy in treatment of severe viral pneumonia,and can effectively improve the pulmonary inflammatory response of patients,shorten the recovery time of clinical symptoms and hospital stay,accelerate the rehabilitation process,which has good safety.
Xuebijing InjectionRibavirn Injectionsevere viral pneumoniaclinical recovery timetime of fever reductionaverage length of hospital staypulmonary imaging improvement rateCRPprocalcitoninCK-MB
NETL
NSTL
万方数据
